InsidersTradesSigma
Follow the Fulcrum Therapeutics, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Fulcrum Therapeutics, Inc. has published 42 reports. Market capitalisation: €293.7m. The latest transaction was disclosed on 20 July 2026 (Acquisition). Among the most active insiders: Gould Robert J. Every trade is free.
42
Insider Decl.
n/a
Thresholds
€31m
16 ops.
Buy Volume
€17m
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Fulcrum Therapeutics, Inc. Hold (neutral), based on 4 analysts. Average price target: US$3.50.
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 July 2026
Declarations42 total
50,945 shares@ US$3.520.074% mcap12.1% of flowCommon StockSEC:0001178579-26-000016:1
Canonical exit: 15 Oct 2026 (T+90)
116,671 shares@ US$3.560.17% mcap27.9% of flowCommon StockSEC:0001178579-26-000016:0
Canonical exit: 14 Oct 2026 (T+90)
75,952 shares@ US$3.580.11% mcap30.6% of flowCommon StockSEC:0001178579-26-000014:2
Canonical exit: 12 Oct 2026 (T+90)
107,377 shares@ US$3.560.16% mcap42.8% of flowCommon StockSEC:0001178579-26-000014:3
Canonical exit: 13 Oct 2026 (T+90)
12,966 shares@ US$3.540.019% mcap5.2% of flowCommon StockSEC:0001178579-26-000014:0
Canonical exit: 11 Oct 2026 (T+90)
53,651 shares@ US$3.560.080% mcap21.5% of flowCommon StockSEC:0001178579-26-000014:1
Canonical exit: 12 Oct 2026 (T+90)
18,000 sharesCommon StockSEC:0001193125-26-290622:0
15,000 shares@ US$10.87260.055% mcap7.8% of flowCommon StockSEC:0001193125-26-037606:0
15,000 shares@ US$10.72380.054% mcap7.6% of flowCommon StockSEC:0001193125-26-037573:0
15,000 shares@ US$11.87260.060% mcap8.5% of flowCommon StockSEC:0001193125-26-004572:0
3,452 shares@ US$12.9282.2% of flowCommon StockSEC:0001193125-25-322740:0
1,377,020 shares@ US$13.3335.5% of flowCommon StockSEC:0001231919-25-000596:0
15,000 shares@ US$11.0339.0% of flowCommon StockSEC:0001193125-25-291392:0
498 shares@ US$5.064.0% of flowCommon StockSEC:0000950170-25-068038:0
8,500,000 sharesCommon StockSEC:0001415889-24-022127:0
150,000 shares@ US$3.2750.0% of flowCommon StockSEC:0000950170-24-081949:0
236 shares@ US$7.763.0% of flowCommon StockSEC:0000950170-24-056947:0
4,884 shares@ US$11.715591.9% of flowCommon StockSEC:0000950170-24-028827:0
43,360 shares@ US$11.347550.0% of flowCommon StockSEC:0000950170-24-025933:0
Canonical exit: 2 Jun 2024 (T+90)
210 shares@ US$3.311.1% of flowCommon StockSEC:0000950170-23-021245:0
1,923,076 shares@ US$13.0080.4% of flowCommon StockSEC:0001104659-23-006213:0
Canonical exit: 20 Apr 2023 (T+90)
6,766 shares@ US$15.005.0% of flowCommon StockSEC:0000899243-23-001803:0
122,334 shares@ US$7.02762.8% of flowCommon StockSEC:0001104659-23-001881:0
Canonical exit: 4 Apr 2023 (T+90)
4,089 shares@ US$5.99410.1% of flowCommon StockSEC:0001104659-22-130982:0
Canonical exit: 27 Mar 2023 (T+90)
98,787 shares@ US$5.89971.9% of flowCommon StockSEC:0001104659-22-129121:0
Canonical exit: 19 Mar 2023 (T+90)
25 of 42 declarations
关于 Fulcrum Therapeutics, Inc.
从地理上看，Fulcrum 的运营足迹集中在波士顿/剑桥生物技术集群，其总部和实验室空间均设于此。该地理位置使其能够接触到人才、学术网络和更广泛的美国生命科学生态系统，但该公司主要仍是一个研发组织，商业基础设施有限。近期亮点包括 pociredir 在 SCD 的 Phase 1b PIONEER 研究中取得积极进展，计划在 2026 年下半年推进潜在的注册支持性试验，以及在 2025 年底通过公开发行股票后现金状况得到改善。总体而言，Fulcrum 仍然是一家在美国纳斯达克全球市场上市的高风险、高回报的罕见病生物技术公司。
